Magnetic field enhanced convective diffusion of iron oxide nanoparticles in an osmotically disrupted cell culture model of the blood-brain barrier

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3013-3026

  Sun, Zhizhi ^a   Worden, Matthew ^b   Wroczynskyj, Yaroslav ^a   Yathindranath, Vinith ^a   van Lierop, Johan ^a   Hegmann, Torsten ^a,b   Miller, Donald W ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b KENT STATE UNIVERSITY   (United States)

Author keywords

Blood brain barrier; Drug delivery; Iron oxide nanoparticles; Magnetic targeting; Permeability

Indexed keywords

AMINOSILANE COATED IRON OXIDE NANOPARTICLE; MANNITOL; N (TRIMETHOXYSILYLPROPYL)ETHYLENEDIAMINETRIACETATE IRON OXIDE NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG; MAGNETITE NANOPARTICLE;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN ENDOTHELIAL CELL; CHEMICAL COMPOSITION; CONTROLLED STUDY; DIFFUSION; ENDOTHELIUM CELL; IN VITRO STUDY; MAGNETIC FIELD; MAGNETIC FIELD ENHANCED CONVECTIVE DIFFUSION; MOUSE; NONHUMAN; OSMOSIS; PARTICLE SIZE; PERMEABILITY; PH; PHYSICAL CHEMISTRY; SYNTHESIS; ANIMAL; CELL LINE; CHEMISTRY; ELECTROPORATION; MAGNETOTHERAPY; PROCEDURES; RADIATION RESPONSE; THERMODYNAMICS;

ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE; CONVECTION; DIFFUSION; ELECTROPORATION; ENDOTHELIAL CELLS; MAGNETIC FIELD THERAPY; MAGNETIC FIELDS; MAGNETITE NANOPARTICLES; MICE;

EID: 84903317310     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S62260     Document Type: Article

References (54)

1. Pardridge WM. Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov Today. 2002;7(1):5-7.
2. Daneman R. The blood-brain barrier in health and disease. Ann Neurol. 2012;72(5):648-672.
3. On NH, Chen F, Hinton M, Miller DW. Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques. Pharm Res. 2011;28(10): 2505-2515.
4. Nicolazzo JA, Katneni K. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). Curr Top Med Chem. 2009;9(2):130-147.
5. Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. Neuro Rx. 2005;2(1):86-98.
6. Zhang Y, Schuetz JD, Elmquist WF, Miller DW. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther. 2004;311(2): 449-455.
7. Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24(9): 1733-1744.
8. Tietze R, Lyer S, Dürr S, Alexiou C. Nanoparticles for cancer therapy using magnetic forces. Nanomedicine (Lond). 2012;7(3):447-457.
9. Zhu L, Wang D, Wei X, et al. Multifunctional pH-sensitive superparamagnetic iron-oxide nanocomposites for targeted drug delivery and MR imaging. J Control Release. 2013;169(3):228-238.
10. Fan CH, Ting CY, Lin HJ, et al. SPIO-conjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-ultrasound enhanced brain-tumor drug delivery. Biomaterials. 2013;34(14):3706-3715.
11. Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano. 2013;7(3):2078-2089.
12. Xu C, Sun S. New forms of superparamagnetic nanoparticles for biomedical applications. Adv Drug Deliv Rev. 2013;65(5):732-743.
13. Kenzaoui BH, Bernasconi CC, Hofmann H, Juillerat-Jeanneret L. Evaluation of uptake and transport of ultrasmall superparamagnetic iron oxide nanoparticles by human brain-derived endothelial cells. Nanomedicine (Lond). 2012;7(1):39-53.
14. Lee MJ, Veiseh O, Bhattarai N, et al. Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. PLoS One. 2010;5(3):e9536.
15. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
16. Alexiou C, Schmid RJ, Jurgons R, et al. Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur Biophys J. 2006;35(5):446-450.
17. On NH, Mitchell R, Savant SD, Bachmeier CJ, Hatch GM, Miller DW. Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model. J Neurooncol. 2013;111(2):133-143.
18. Sun Z, Yathindranath V, Worden M, et al. Characterization of cellular uptake and toxicity of aminosilane-coated iron oxide nanoparticles with different charges in central nervous system-relevant cell culture models. Int J Nanomedicine. 2013;8:961-970.
19. Yathindranath V, Rebbouh L, Moore DF, Miller DW, van Lierop J, Hegmann T. A versatile method for the reductive, one-pot synthesis of bare, hydrophilic and hydrophobic magnetite nanoparticles. Adv Funct Mater. 2011;21(8):1457-1464.
20. Yathindranath V, Sun Z, Worden M, et al. One-pot synthesis of iron oxide nanoparticles with functional silane shells: a versatile general precursor for conjugations and biomedical applications. Langmuir. 2013;29(34):10850-10858.
21. Hoff D, Sheikh L, Bhattacharya S, Nayar S, Webster TJ. Comparison study of ferrofluid and powder iron oxide nanoparticle permeability across the blood-brain barrier. Int J Nanomedicine. 2013;8:703-710.
22. Li G, Simon MJ, Cancel LM, et al. Permeability of endothelial and astrocyte cocultures: in vitro blood-brain barrier models for drug delivery studies. Ann Biomed Eng. 2010;38(8):2499-2511.
23. Berne BJ, Pecora R. Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics. New York: Dover Publications; 2000.
24. Wang J, Chen Y, Chen B, et al. Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticles in mice. Int J Nanomedicine. 2010;5:861-866.
25. Petri B, Bootz A, Khalansky A, et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release. 2007; 117(1):51-58.
26. Qiao R, Jia Q, Hüwel S, et al. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier. ACS Nano. 2012;6(4): 3304-3310.
27. Etame AB, Smith CA, Chan WC, Rutka JT. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomedicine. 2011;7(6):992-1000.
28. Boockvar JA, Tsiouris AJ, Hofstetter CP, et al. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg. 2011;114(3):624-632.
29. Kiptoo P, Sinaga E, Calcagno AM, et al. Enhancement of drug absorption through the blood-brain barrier and inhibition of intercellular tight junction resealing by E-cadherin peptides. Mol Pharm. 2011;8(1): 239-249.
30. On NH, Savant S, Toews M, Miller DW. Rapid and reversible enhancement of blood-brain barrier permeability using lysophosphatidic acid. J Cereb Blood Flow Metab. 2013;33(12):1944-1954.
31. Borlongan CV, Glover LE, Sanberg PR, Hess DC. Permeating the blood brain barrier and abrogating the inflammation in stroke: implications for stroke therapy. Curr Pharm Des. 2012;18(25):3670-3676.
32. Hynynen K. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev. 2008;60(10):1209-1217.
33. Muldoon LL, Nilaver G, Kroll RA, et al. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol. 1995;147(6):1840-1851.
34. Liu HL, Hua MY, Yang HW, et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci U S A. 2010;107(34): 15205-15210.
35. Burgess A, Hynynen K. Noninvasive and targeted drug delivery to the brain using focused ultrasound. ACS Chem Neurosci. 2013;4(4): 519-526.
36. Carenza E, Barceló V, Morancho A, et al. In vitro angiogenic performance and in vivo brain targeting of magnetized endothelial progenitor cells for neurorepair therapies. Nanomedicine. 2014;10(1):225-234.
37. Kong SD, Lee J, Ramachandran S, et al. Magnetic targeting of nanoparticles across the intact blood-brain barrier. J Control Release. 2012;164(1):49-57.
38. Chertok B, David AE, Yang VC. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J Control Release. 2011;155(3):393-399.
39. Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29(4):487-496.
40. Zhang J, Shin MC, Yang VC. Magnetic targeting of novel heparinized iron oxide nanoparticles evaluated in a 9L-glioma mouse model. Pharm Res. 2014;31(3):579-592.
41. Delgado AV, González-Caballero F, Hunter RJ, Koopal LK, LyklemaJ; International Union of Pure and Applied Chemistry, Physical and Biophysical Chemistry Division IUPAC Technical Report. Measurement and interpretation of electrokinetic phenomena. J Colloid Interface Sci. 2007;309(2):194-224.
42. Lesniak A, Salvati A, Santos-Martinez MJ, Radomski MW, Dawson KA, Åberg C. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J Am Chem Soc. 2013; 135(4):1438-1444.
43. Jedlovszky-Hajdú A, Bombelli FB, Monopoli MP, Tombácz E, Dawson KA. Surface coatings shape the protein corona of SPIONs with relevance to their application in vivo. Langmuir. 2012;28(42): 14983-14991.
44. Ruh H, Kühl B, Brenner-Weiss G, Hopf C, Diabaté S, Weiss C. Identification of serum proteins bound to industrial nanomaterials. Toxicol Lett. 2012;208(1):41-50.
45. Safi M, Courtois J, Seigneuret M, Conjeaud H, Berret JF. The effects of aggregation and protein corona on the cellular internalization of iron oxide nanoparticles. Biomaterials. 2011;32(35):9353-9363.
46. Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials. 2012;33(32):8167-8176.
47. Yemişci M, Gürsoy-Özdemir Y, Caban S, Bodur E, Capan Y, DalkaraT. Transport of a caspase inhibitor across the blood-brain barrier by chitosan nanoparticles. Methods Enzymol. 2012;508:253-269.
48. Lu W, Wan J, She Z, Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release. 2007;118(1):38-53.
49. McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials. 2009; 30(23-24):3986-3995.
50. Ke W, Shao K, Huang R, et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials. 2009;30(36):6976-6985.
51. Chen W, Zhan C, Gu B, et al. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles. J Drug Target. 2011;19(3):228-234.
52. van Rooy I, Mastrobattista E, Storm G, Hennink WE, Schiffelers RM. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release. 2011;150(1):30-36.
53. Xie Y, Ye L, Zhang X, et al. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. J Control Release. 2005;105(1-2):106-119.
54. Georgieva JV, Kalicharan D, Couraud PO, et al. Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood-brain barrier endothelial cells in vitro. Mol Ther. 2011;19(2):318-325.